Kosugi A, Fujiwara H, Hamaoka T
Gan To Kagaku Ryoho. 1984 Aug;11(8):1527-35.
Recent progress in tumor-specific immunotherapy was reviewed. Methods involved include a) utilization of tumor-specific monoclonal antibodies in conjugation with various anti-cancer agents, b) adoptive transfer of anti-tumor effector T cell clones elaborated in vitro in the presence of interleukin-2 and c) active tumor-specific immunotherapy by augmenting the generation of tumor specific effector T cells. This paper focused especially on the amplified induction of tumor-specific immunity by T-T cell interaction between helper T cells and anti-tumor effector T cells. Data were provided indicating successful tumor-specific immunotherapy in autochthonous as well as syngeneic tumor models and such results were discussed in the light of the future clinical application of the tumor-specific active immunotherapy.
本文综述了肿瘤特异性免疫疗法的最新进展。所涉及的方法包括：a）将肿瘤特异性单克隆抗体与各种抗癌药物结合使用；b）在白细胞介素-2存在的情况下，体外制备抗肿瘤效应T细胞克隆并进行过继性转移；c）通过增强肿瘤特异性效应T细胞的生成进行主动肿瘤特异性免疫疗法。本文特别关注辅助性T细胞与抗肿瘤效应T细胞之间的T-T细胞相互作用对肿瘤特异性免疫的放大诱导作用。文中提供的数据表明，在自体肿瘤模型和同基因肿瘤模型中，肿瘤特异性免疫疗法均取得了成功，并根据肿瘤特异性主动免疫疗法的未来临床应用对这些结果进行了讨论。
